Sybron International, hardly a well-known name in the diagnostics industry, has built a $350 million highly profitable diagnostics business by acquiring small, niche companies. Its latest acquisition, Microgenics Corp., makes it an important player in the drugs of abuse and therapeutic drug monitoring businesses. Microgenics had been part of Boehringer Mannheim Corp. But when Roche bought Boehringer Mannheim, the FTC required Roche to sell off Microgenics for anti-trust reasons. Microgenics was sold last summer to an investor group, which sold it to Sybron.
Hardly a well-known name, Sybron International Corp. , has quietly amassed a $350 million highly
profitable diagnostics business over the years by acquiring
well-run niche companies—and now considers itself the tenth
largest company in the industry. Its latest acquisition,
Microgenics Corp. [See Deal],
strengthens its position in one of its core businesses—making
reagents for drugs of abuse (DOA) testing and therapeutic drug
monitoring (TDM).
Sybron is already a major OEM supplier of TDM and DOA reagents to Roche , Beckman Coulter Inc. ...